DaVita HealthCare Partners Rating Lowered to Market Perform at Raymond James (DVA)
DaVita HealthCare Partners (NYSE:DVA) was downgraded by investment analysts at Raymond James from an “outperform” rating to a “market perform” rating in a note issued to investors on Monday, TheFlyOnTheWall.com reports.
Shares of DaVita HealthCare Partners (NYSE:DVA) traded down 3.62% during mid-day trading on Monday, hitting $71.18. The stock had a trading volume of 786,069 shares. DaVita HealthCare Partners has a 52-week low of $52.75 and a 52-week high of $74.84. The stock’s 50-day moving average is $72.14 and its 200-day moving average is $68.48. The company has a market cap of $15.247 billion and a price-to-earnings ratio of 20.19.
DaVita HealthCare Partners (NYSE:DVA) last announced its earnings results on Thursday, May 1st. The company reported $0.85 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.86 by $0.01. The company had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $3.02 billion. During the same quarter in the previous year, the company posted $1.84 earnings per share. The company’s revenue for the quarter was up 7.5% on a year-over-year basis. On average, analysts predict that DaVita HealthCare Partners will post $3.64 earnings per share for the current fiscal year.
A number of other firms have also recently commented on DVA. Analysts at Zacks reiterated a “neutral” rating on shares of DaVita HealthCare Partners in a research note on Wednesday, July 16th. They now have a $77.00 price target on the stock. Separately, analysts at Jefferies Group initiated coverage on shares of DaVita HealthCare Partners in a research note on Monday, June 30th. They set a “buy” rating and a $86.00 price target on the stock. Finally, analysts at Susquehanna initiated coverage on shares of DaVita HealthCare Partners in a research note on Monday, June 16th. They set a “neutral” rating and a $75.00 price target on the stock. Five research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. DaVita HealthCare Partners currently has an average rating of “Buy” and a consensus target price of $80.11.
DaVita HealthCare Partners Inc, formerly DaVita Inc, is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease (NYSE:DVA).
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.